Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Psychiatry Pharmacology > Antipsychotic Drugs > Flashcards

Antipsychotic Drugs Flashcards

1
Q

PRIMARY DRUGS

A 
CHLORPROMAZINE (Typical)
FLUPHENAZINE  (Typical)
HALOPERIDOL  (Typical)
ARIPIPRAZOLE (Atypical)
CLOZAPINE (Atypical)
OLANZAPINE (Atypical)
RISPERIDONE (Atypical)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Secondary Drugs

A 
perphenazine (Typical)
thiothixene (Typical)
paliperidone (Atypical)
quetiapine (Atypical)
ziprasidone (Atypical)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Phenothiazenes =

A

zine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

2nd Generation drugs with highest potential for CYP-interactions (3A4/2D6)

A

Risperidone, Aripiprazole, Quetiapine, Ziprasidone

Think RAQZ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

2nd Generation Antipsychotics that are most likely to cause Diabetes & Weight Gain

A

Clozapine

Olanzapine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

2nd Generation Antipsychotics most likely to cause EPS

A

Risperidone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

2nd Generation Antipsychotics least likely to cause QTc Prolongation

A

Aripirazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

2nd Generation Antipsychotics most likely to cause QTc Prolongation

A

Ziprasidone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

2nd Generation Antipsychotics that cause Elevated

Prolactin

A

Palperidone

Risperidone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Definition of Psychosis

A

A symptom of a major mental disorder in which:
 Personality is seriously disorganized
 Contact with reality is usually impaired
 Ability to think, perceive, and judge is impaired (often with delusions and/or hallucinations)
 Ability to communicate & relate to others is impaired
 Ability to cope with the environment is impaired
 Ability to meet the ordinary demands of life is impaired

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Diagnostic Criteria for Schizophrenia

Characteristic Symptoms:

A

2 or more, each present for a significant proportion of the time for 1 month (or less if treated)
 Delusions
 Hallucinations
 Disorganized Speech
 Grossly disorganized or catatonic behavior
 Negative symptoms (affective flattening, alogia, or avolition)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Diagnostic Criteria for Schizophrenia

Include:

A

 Social/Occupational Dysfunction
 Signs of the disturbance present for 6 months or longer
 Schizoaffective and mood disorders have been ruled out
 Substance abuse and general medical conditions have been ruled out
 In presence of autism, hallucinations or delusions present for over 1 month

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Idiopathic Psychosis

Positive Symptoms

A

 Delusions
 Hallucinations
 Disorganized speech
 Disorganized or catatonic behavior

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Idiopathic Psychosis

Negative Symptoms

A

 Impoverished thoughts
 Deficits of attention
 Blunt affect
 Lack of initiative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Receptors Clinical potency correlates with

A

in vitro inhibition of D2 receptor binding.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Receptors Other

A

Muscarinic, alpha-adrenergic, histamine H1 and serotonin 5-HT2 receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Receptors Atypical antipsychotics

A

 Low D2 affinity

 High 5-HT2 affinity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Treatment of Psychosis

Antipsychotics Factors:

A

 Typical vs. Atypical

 Low Potency vs. High Potency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Typical Antipsychotics: Definition

A

 Dopamine D2 blockers
 Produce extrapyramidal symptoms (EPS)
 Elevate prolactin (PRL) levels
 Equally effective but differ in potency/side effects
 Largely effective for positive symptoms (e.g., delusions, hallucinations, disorganization of thought and behavior)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Atypical Antipsychotics: Definition

A

 Share D2 and 5HT2A antagonism in common
 Addition of 5HT2A blockade may:
- reduce EPS
- improve efficacy for negative symptoms e.g., withdrawal, flat affect, paucity of thought,
avolition (poor initiation of goal directed
behavior)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Antipsychotics

A

 Phenothiazines
 Thioxanthenes
 Butyrophenones (phenylbutylpiperidines)
& Diphenylbutylpiperidines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Chlropromazine Structure

A

Aliphatic side chain

Low potency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Thiothixene Structure

A

Piperidine ring in side chain

Lower incidence of EPS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Fluphenazine & Perphenazine Structure

A

Piperazine group in side chain

Potent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Butyrophenones example

A

 Haloperidol

 High potency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Clozapine Type/Potency

A

 Low potency
 Atypical antipsychotic
 Olanzapine and Quetiapine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Risperidone Receptor/Beneifits

A 
 5-HT2/D2 antagonist
 Limited EPS at low doses
 Only approved agent for use in children and teens
 Paliperidone
• Active metabolite
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Aripiprazole Receptor/Potency

A

 D2 partial agonist
 Reduces actions of full agonist
 5-HT2A antagonist, 5-HT1A partial agonist
 Lower incidence of side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Ziprasidone Receptor/Side Effects

A

 5-HT2A, 5-HT1A, 5-HT2C/D2 antagonist

 Limited EPS

30
Q

Neuroleptic Syndrome Define:

A

 Suppression of spontaneous movements and
complex behaviors
 Reduced initiative and interest in environment
 Decreased manifestations of emotion or affect
 Psychotic symptoms disappear over time

31
Q

CNS Effects Cerebral Cortex

A 
 Minimal adaptive changes in dopamine
system
 Can lower seizure thresholds
 More likely with low potency phenothiazines
 Butyrophenones unpredictable
 More likely in predisposed patients
32
Q

CNS Effects Basal Ganglia

A

 Suggested that decreased dopamine activity
associated with extrapyramidal side effects (EPS)
 Antipsychotics consistently increase dopamine
metabolism
 Antipsychotic effects not thought to occur here
 Initially increase dopamine metabolism, synthesis and firing rate
 Diminishes with time

33
Q

CNS Effects Limbic System

A

 Thought to be site of antipsychotic effects

 Anticholinergics do not block therapeutic effect

34
Q

CNS Effects Hypothalamus

A

 Increased prolactin secretion
 Little tolerance
 Avoid in patients with established breast carcinoma

35
Q

Effects on Prolactin Secretion

A 
Interference with dopamine secretion or action leads to an increase in serum prolactin
All Typicals     Increased
Risperidone     Increased
Clozapine        Little Increase
Olanzapine      Little Increase
Ziprasidone      Little Increase
Quetiapine       No Increase
Aripiprazole      No Increase (decrease?)
36
Q

Clinical Consequences of Sustained Hyperprolactinemia

A

Sexual dysfunction
Amenorrhea
Gynecomastia/Galactorrhea
Hypoestrogenism/Osteopenia?

37
Q

CNS Effects Brainstem

A

 Little effect on respiration
 Decreased vasomotor reflexes
 Occurs at low doses

38
Q

CNS Effects Chemoreceptor Trigger Zone

A

 Protect against nausea and vomiting elicited by activation of dopamine receptors
 Occurs at low doses

39
Q

Autonomic Nervous System

A

Complex and unpredictable

40
Q

Renal System

A

Chlorpromazine may be antidiuretic

41
Q

Hepatic System

A

 No characteristic effects

 May be toxic in patients with liver disease

42
Q

Endocrine System Chlorpromazine Side Effects

A

 Impairs glucose tolerance

 Decreases insulin release

43
Q

Endocrine System Drugs that Increased risk of Type II diabetes

A

Clozapine, risperidone, aripiprizole,

ziprasidone, olanzepine and quetiapine

44
Q

Cardiovascular System Effects

A

 Direct effects on heart and vessels
 Indirect effects via CNS and ANS
 Mild orthostatic hypotension
- More so with chlorpromazine, thioridazine
- Less so with haloperidol, loxapine, risperidone
- Tolerance develops

45
Q

May increase acetylcholine turnover

A

Mainly basal ganglia

46
Q

Inverse relationship between antimuscarinic

potency and

A

EPS

47
Q

Toxic Reactions/Side Effects

A 
 High Therapeutic Index
 Anticholinergic Effects
    - Nasal stuffiness
    - Dry mouth
    - Blurred vision
    - Constipation
    - Cardiovascular
    - Orthostatic Hypotension
48
Q

Extrapyramidal Side Effects

A 
 Acute Dystonia
 Akathesia
 Parkinsonian Syndrome
 Neuroleptic Malignant Syndrome
 Perioral Tremor
 Tardive Dyskinesia
49
Q

Acute Dystonia Symptoms/Treatment

A 
Symptoms
 Muscle spasms
 Facial Grimacing
 Torticollis: stiff neck
 Oculogyeric crisis
Treatment
 Anticholinergic antiparkinsonian agents
50
Q

Akathesia Symptoms/Treatment

A 
Symptoms
 Strong subjective feelings of distress or discomfort often referred to the legs
 "Ants in the pants"
Treatment
 Decrease dose
 Add antiparkinsonian agent
 Antianxiety agent or propranolol
51
Q

Parkinsonian Syndrome Symptoms/Treatment

A 
Symptoms
 Akinesia
 Mask facies
 Decreased arm movement
 Rigidity
 Tremor
Treatment
 Anticholinergic antiparkinsonian agents
 Amantadine
52
Q

Neuroleptic Malignant Syndrome

A 
 Rare
 Fever
 Severe Parkinsonism with catatonia
 Fluctuations in coarse tremor intensity
 Autonomic instability
 Elevated creatine kinase
 Myoglobinemia
 High mortality (10%)
53
Q

Neuroleptic Malignant Syndrome Treatment

A

Treatment
 Immediate cessation of antipsychotic
 Supportive care
 Dantrolene or bromocriptine may help

54
Q

Perioral Termor

A

 Rare
 Rabbit syndrome
 Treat with anticholinergic agents
 Stop neuroleptic

55
Q

Tardive Dyskinesia

A

 Stereotyped, repetitive, quick choeriform (tic-like) movements of face eyelids (blinks or spasms), mouth (grimaces), tongue, extremities or trunk
 No adequate treatment
 Discontinue antipsychotic
 Symptoms fade with time

56
Q

Side Effects Jaundice

A

 Occurs during 2nd-4th week with chlorpromazine
 Hypersensitivity reaction
 Mild
 Change agents

57
Q

Side Effects Blood Dyscrasis

A

 Mild leukocytosis, leukopenia, eosinophilia
 Especially important when using clozapine
 Leukopenia may be forewarning of impending agranulocytosis
 Weekly white blood cell counts

58
Q

Side Effects Skin Reactions

A 
 Urticaria or dermatitis
 5% of patients on chlorpromazine
 More common with phenothiazines
 Occur in first 8 weeks
 Skin clears with discontinuation
 Photosensitivity
59
Q

Side Effects Weight Gain

A

 Clozapine, Olanzapine more likely
 Risperidone, Quetiapine, intermediate risk
 Ziprasidone, Aripiprazole, Asenapine less
likely
 Increased risk of Type II diabetes mellitus,
hypertension and hyperlipidemia
 Children/Adolescents
 Atypicals lead to weight gain

60
Q

Metabolic Syndrome

A

 Abdominal obesity
 Atherogenic dyslipidemia (blood fat disorders —
high triglycerides, low HDL cholesterol and high LDL cholesterol)
 Elevated blood pressure
 Insulin resistance or glucose intolerance
 Prothrombotic state (e.g., high fibrinogen or
plasminogen activator inhibitor–1)
 Proinflammatory state (e.g., elevated C-reactive
protein)

61
Q

Incidence of Metabolic Syndrome on Atypical Antipsychotics

A 
Drug Incidence
Olanzapine High
Quetiapine Moderate
Risperidone Moderate
Zisprasidone Low
Aripiprazole Low
62
Q

EPS & hyperprolactinemia—

A

D2 blockade

63
Q

Hypotension—

A

alpha adrenergic blockade

64
Q

Sedation—

A

histaminergic blockade

65
Q

Weight gain—

A

histaminic & serotonergic blockade

66
Q

Anticholinergic (e.g., dry mouth)—

A

muscarinic blockade

67
Q

Sexual side effects—

A

serotonergic, muscarinic, noradrenergic and D2 (via prolactin) blockade

68
Q

Pharmacokinetics

A

 Oral absorption erratic
 Bioavailability increase 4-10x when given
intramuscularly
 Highly lipophilic
 Highly protein and membrane bound
 Accumulates in high blood supply tissues
 Crosses placental barrier and enters breast milk
 Biological effect usually lasts 24 hr
 Give entire daily dose at once

69
Q

Metabolism

A 
 Oxidation main route
    - Hepatic microsomal oxidases and conjugation
 Most metabolites inactive
 Exceptions
    - 7-OH-chlorpromazine
    - Several N-methylated metabolites of phenothiazines
     -  Paliperidone
     - Dehydroaripirazole
70
Q

Tolerance/Physical Dependence

A

 Not addicting
 Some physical dependence
 Malaise, difficulty sleeping if abrupt stoppage
 Tolerance develops to sedative effects over days to weeks

71
Q

Drug Interactions Typical Antipsychotics

A

 Metabolized at 2D6 and 3A4
 Do not induce P 450 enzymes
 Many inhibit 2D6
- Raise levels of many TCAs and SSRIs
- Raise levels of many other antipsychotics
 Theoretically vulnerable to inducers and inhibitors of 2D6 and 3A4, though little is known about this in vivo

Psychiatry Pharmacology (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions